AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If the information provided is not complete, correct, or legible, the authorization process can be delayed.

Drug Requested: Compound Drug(s)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:	
Member AvMed #:	
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	

Ingredients:

Drug	Strength	Drug	Strength

The Compound **must** contain at least **one FDA-approved** prescription drug and the prescription ingredients **must** be in therapeutic amounts recognized by national compendia or peer-reviewed medical literature.

Indication:

Dosage form of compound: _____

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

□ National Compendia reference or two (2) peer-reviewed randomized controlled trials supporting the efficacy and safety of this compound are attached to this request.

AND

(Continued on next page)

Patient has tried and failed at least three (3) FDA-approved commercially available therapeutic
alternatives and at least one of the alternatives is of the same route of administration as the compound:

□ Drug:	Route of administration:
Drug:	Route of administration:
Drug:	Route of administration:

<u>AND</u>

□ The strength requested is **not** commercially available

Compounds containing the following must be in the same dosage form as commercially available specific drug products: diclofenac, flurbiprofen, fluticasone, gabapentin, ketamine, ketoprofen, levoceterizine and mometasone.

Compounds used for cosmetic indications are excluded from benefit and will be denied

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. *<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>*